Hikma Pharmaceuticals PLC EBIT

Hikma Pharmaceuticals PLC (HKMPF) currently reports a EBIT of $1.2B as of June 2026. That compares with $980M in the prior-year period — up 26.7% year over year. That is above the sector sector average of $-25M. Use the charts on this page to explore Hikma Pharmaceuticals PLC's EBIT history and peer comparisons.

Hikma Pharmaceuticals PLC's EBIT increased from $980M to $1.2B — a 26.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Hikma Pharmaceuticals PLC's EBIT of $1.2B is higher than the its sector sector average of $-25M. That is roughly 5016.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Hikma Pharmaceuticals PLC reported $1.2B in EBIT as of June 2026. That compares with $980M in the prior-year period — up 26.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $1.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-25M. From there, open related valuation or income-statement pages for Hikma Pharmaceuticals PLC, and consider following HKMPF for alerts when major investors trade the stock.